300
Participants
Start Date
December 12, 2024
Primary Completion Date
October 1, 2029
Study Completion Date
October 1, 2029
Omaveloxolone
Administered as specified in the treatment arm.
NOT_YET_RECRUITING
Ospedale Pediatrico Bambino Gesu, Rome
NOT_YET_RECRUITING
HUB-Hôpital Erasme, Brussels
RECRUITING
Medizinische Universität Innsbruck, Innsbruck
NOT_YET_RECRUITING
Stichting Radboud universitair medisch centrum, Nijmegen
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
NOT_YET_RECRUITING
Fondazione I.R.C.C.S. Istituto Neurologico C. Besta, Milan
NOT_YET_RECRUITING
Scientific Institute, IRCCS E. Medea, Conegliano
NOT_YET_RECRUITING
University of Florida, Gainesville
NOT_YET_RECRUITING
University Hospital Aachen, Aachen
RECRUITING
Universitätsklinikum Tübingen, Tübingen
RECRUITING
University of Colorado, Aurora
NOT_YET_RECRUITING
Klinikum der Universität München, Munich
NOT_YET_RECRUITING
UCLA Neurology, Los Angeles
RECRUITING
Center for hereditary ataxias, Motol, Motol
Lead Sponsor
Biogen
INDUSTRY